J Transl Med 2023, **21**(Suppl 1):35
https://doi.org/10.1186/s12967-022-03800-1

Journal of Translational Medicine

MEETING ABSTRACTS

Meeting abstracts from the 10th International Conference on cGMP: Generators, Effectors and Therapeutic Implications

Augsburg, Germany. 17–19 June 2022

Published: 31 January 2023

ORAL PRESENTATIONS

Session 1 | Pre-Clinical Translation & Back-Translation

O1

Applying translational approaches for the nonclinical and clinical evaluation of the sGC stimulator CY6463 in CNS diseases

Christopher J. Winrow
Cyclerion Therapeutics, Cambridge Massachusetts, USA
Correspondence: Christopher J. Winrow (cwinrow@cyclerion.com)
J Transl Med 2022, **21(1)**:O1

Introduction: The NO-sGC-cGMP pathway plays a critical role in central nervous system (CNS) function and is impacted across a range of neurological and psychiatric diseases. NO is recognized as a key neurotransmitter that is produced on-demand within the CNS and can act through sGC and cGMP to govern a range of downstream effects. We have identified CY6463, a CNS-penetrant sGC stimulator, with demonstrated pharmacological effects in nonclinical and clinical studies. By acting as a selective positive allosteric modulator of sGC, CY6463 can amplify endogenous NO signaling while maintaining upstream spatial and temporal regulation. This enables the on-demand production of cGMP and propagation of downstream signals within the CNS.
Methods: A range of nonclinical studies were conducted to understand the in vitro and in vivo properties of CY6463 and supported advancement into clinical development. Phase 1 clinical studies included single-ascending dose, multiple-ascending dose and food interaction studies along with a translational pharmacology study in healthy elderly participants.
Results: This presentation will describe the nonclinical pharmacology of CY6463, along with clinical data from Phase 1 studies including the pharmacokinetic, safety, and pharmacodynamic results of our clinical translational pharmacology study in elderly participants. Furthermore, we will discuss our translational biomarker strategy that has been carried through into clinical studies in three separate patient populations and provide outlines of these clinical studies and updates on progress to date.
Conclusions: Applying a translational biomarker based approach to the development of CY6463 has enabled advancement of clinical studies in well-defined patient populations to help understand the potential opportunity for modulating sGC function in neuropsychiatric and neurodegenerative diseases.
Acknowledgements: CJW is an employee of Cyclerion Therapeutics and gratefully acknowledges the contributions of the Cyclerion team members and collaborators to this project.

O2

sGC modulators as cognitive enhancers: neuronal and/or vascular?

Jos Prickaerts[1], Ellis Nelissen[1], Tim Vanmierlo[1,2], Peter Sandner[3,4]
[1]Maastricht University, Psychiatry and Neuropsychology, Maastricht, Netherlands; Hasselt University, Biomedical Research Institute, Hasselt, Belgium; [3]Bayer AG, Cardiovascular Research, Wuppertal, Germany; [4]Hannover Medical School, Hannover, Germany
Correspondence: Jos Prickaerts (jos.prickaerts@maastrichtuniversity.nl)
J Transl Med 2022, **21(1)**:O2

Introduction: Cognitive impairment is one of the main symptoms of Alzheimer's disease or Vascular dementia, which negatively impacts the quality of life of patients. Therefore, a pharmacological intervention that has memory enhancing effects would be beneficial to patients. Vascular dementia is characterized by impairments in cerebral blood flow, endothelial function and blood–brain barrier integrity. These processes are all physiologically regulated by the soluble guanylate cyclase (sGC)-cGMP signaling pathway in blood vessel cells. Additionally, neuronal cGMP signaling plays an important role in long-term potentiation underlying memory formation. Therefore, targeting the NO-sGC-cGMP pathway may be a therapeutic strategy for treating neuronal- and/or vascular-based dementias.
Methods: sGC stimulators acting on heme-bound sGC and one sGC activator acting on heme-free sGC were tested in the object location task (OLT) on acquisition memory processes, in healthy rodents and in deficit models. Vascular function and neuroplasticity were assessed.

Results: The non-brain penetrant sGC stimulators riociguat and vericiguat improved memory acquisition in the OLT in rodents. Riociguat attenuated memory deficits in a cerebral vasoconstriction model for memory impairment induced by sumatriptan. The effective doses of vericiguat had no effect on mean arterial blood pressure and cerebral blood volume. This suggests that non-brain penetrant sGC stimulators improve memory via an effect on the cerebral microvasculature. The brain penetrant sGC stimulator BAY-747 and activator runcaciguat both improved memory acquisition in the OLT in rats. Interestingly only BAY-747 reversed the NOS inhibitor L-NAME induced memory impairment. Both BAY-747 and runcaciguat increased mBDNF levels in the hippocampus. Both drugs also enhanced GluA1-containing AMPA receptors trafficking in a chemical LTP model for memory acquisition using mouse hippocampal slices. Yet, only for runcaciguat this involved phosphorylation of the receptor on S845.
Conclusions: Both sGC stimulators and activators have potential as cognitive enhancers. sGC stimulators have effects on microvasculature as well as neuroplasticity. Effects on neuroplasticity are also exerted by sGC activators, yet with different underlying mechanisms than sGC stimulators. Further elucidating these properties will help in determining which type of sGC modulator can optimally improve cognition in a vascular and/or neuronal type of dementia.
Funding: Funding was in part supported by a restricted grant from Bayer AG and Merck Sharp & Dohme Corp.

O3

Discovery and preclinical profiling of the oral sGC activator runcaciguat (BAY 1101042): a novel and effective treatment approach for chronic kidney disease?

Peter Sandner[1,2]
[1]Bayer AG, Research and Early Development, Wuppertal, Germany; [2]Hannover Medical School, Department of Pharmacology, Hannover, Germany
Correspondence: Peter Sandner (peter.sandner@bayer.com)
J Transl Med 2022, **21(1)**:O3

Peter Sandner is presenting on behalf of the entire research and development teams working on runcaciguat (BAY 1101042) in recent years, especially Michael G. Hahn [1], Thomas Lampe [1], Sherif El Sheikh 1], Niels Griebenow [1], Elisabeth Woltering [1], Karl-Heinz Schlemmer [1], Lisa Dietz [1], Michael Gerisch [1], Frank Wunder [1], Eva Maria Becker-Pelster [1], Thomas Mondritzki [1,2], Hanna Tinel [1], Andreas Knorr [1], Achim Kern [1], Dieter Lang [1],Tibor Schomber [1], Agnes Benardeau [2], Antje Kahnert [1], Laura Popp [1], Julia Vienenkoetter [1], Heidrun Ellinger-Ziegelbauer [1], Mira Pavkovic [1], Axel Kretschmer [1], Bettina Lawrenz [1], Elke Hartmann [1], Krystyna Siudak [1], Alexius Freyberger [1], Ina Hagelschuer [1], Jutta Meyer [1], Jan R. Kraehling [1], Ilka Mathar [1], Joachim Mittendorf [1], Hubert Truebel [2,4], Joerg Hueser [1], Volker Geiss [1], Frank Eitner [1,5], and Johannes-Peter Stasch [1,6];

[1]Bayer AG, Research and Early Development, Pharma Research Center, 42096 Wuppertal, Germany,
[2]University of Witten/Herdecke, 58455 Witten, Germany,
[3]Current employer: Novo Nordisk A/S, Cardio-Renal Biology, Måløv, Denmark Novo Nordisk,
[4]Current employer: AiCuris AG, Wuppertal, Germany,
[5]Division of Nephrology and Clinical Immunology, RWTH Aachen University, 52062 Aachen, Germany,
[6]Institute of Pharmacy, University Halle-Wittenberg, 06120 Halle, Germany,
[7]Department of Pharmacology, Hannover Medical School, 30625 Hannover, Germany.

Introduction: The class of sGC activators has an unique mode of action by activating the oxidized and heme-free form of sGC which is not responsive to nitric oxide (NO). The sGC activators can restore cGMP signaling under oxidative stress conditions, which is present in a variety of diseases and which could potentially result in a broad therapeutic profile of the sGC activators. However, the first generation of sGC activators exhibits limitations and was discontinued. With the discovery of the novel, oral sGC activator runcaciguat (BAY 1101042), the second generation of sGC activators is available with improved solubility, permeability, metabolism, and drug-drug interactions parameters. The discovery and preclinical profiling of runcaciguat in vitro, ex vivo, and in vivo, in both mechanistic and disease models, will be presented.
Methods: Runcaciguat was broadly profiled in vitro, ex vivo, and in vivo. Runcaciguat was tested in mechanistic in vitro, and ex vivo assays and mechanistically studied in vivo models. Moreover, runcaciguat, was tested in different disease models, especially in models for CKD with different etiologies and comorbidities.
Results: Runcaciguat exhibits the profile of a potent and selective sGC activator, which independently of NO stimulates cGMP production in vitro, on the isolated sGC enzyme as in cellular tests. Ex vivo, runcaciguat can relax vascular tissues in different vascular beds. In vivo, runcaciguat leads to a dose-dependent decrease in blood pressure. In different rat CKD models, in renin transgenic (RenTG) and angiotensin-supplemented (ANG-SD) rats, but also in rats with diabetic and metabolic CKD, e.g. the Zucker diabetic fatty (ZDF) rat and ZSF-1 rat, runcaciguat significantly reduced proteinuria. In addition, biomarkers and histopathological markers of kidney damage were also significantly reduced. These kidney-protective effects were also significant at doses that did not or only moderately decrease systemic blood pressure.
Conclusions: In summary, these data demonstrate that runcaciguat (BAY 1101042) exhibits a typical profile of an oral sGC activator in vitro, ex vivo, and in vivo. Moreover, runcaciguat treatment leads to significant renal protection at doses that do not reduce blood pressure and is effective in hypertensive as well as diabetic and metabolic CKD models. Therefore, the sGC activator runcaciguat could represent an efficient treatment approach for CKD (Figure 1). Runcaciguat is currently developed in phase 2 in patients with chronic kidney disease (CONCORD trial, NCT04507061).



Figure 1. Targeting CKD with the sGC activator runcaciguat (BAY 1101042)